This is a significant pipeline catalyst for a $30M market cap company. Monitor for potential partnering interest, financing announcements to fund Phase 2, and any follow-up data presentations at medical conferences. The positive imaging data in PDAC, a high-unmet-need indication, could attract strategic interest from larger radiopharma players.
Price Chart
Executive Summary
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 in pancreatic ductal adenocarcinoma (PDAC), demonstrating favorable safety, biodistribution, and significant tumor uptake in metastatic lesions. The data support advancement into Phase 2 development for a disease with high unmet need and limited imaging options, providing a meaningful pipeline catalyst for this clinical-stage radiopharmaceutical company.
Key Facts
- Positive safety and favorable biodistribution seen in all subjects dosed in Phase 1 imaging trial of RAD301
- Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake
- RAD301 targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth
- RAD301 has previously received Orphan Drug Designation (ODD) from the FDA
- Low background uptake in liver, lung, and bowel supports potential to distinguish metastatic lesions from normal tissue
- Data support continuation of clinical development into Phase 2
Financial Impact
No financial figures provided; this is a clinical data readout for a pre-revenue biotech. The positive data supports pipeline value and potential for future partnering or financing.
Risk Factors
- Phase 1 imaging data, while positive, is early-stage and does not guarantee success in larger Phase 2 therapeutic trials
- Company is pre-revenue and will require additional capital to fund further clinical development
- Pancreatic cancer is a notoriously difficult disease to treat, and imaging agent success does not guarantee therapeutic success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-098219 |
| Document: ea030493201ex99-1.htm | 0001213900-26-098219 |
| Document: 0001213900-26-098219-index-headers.html | 0001213900-26-098219 |
| Document: 0001213900-26-098219-index.html | 0001213900-26-098219 |
| Document: 0001213900-26-098219.txt | 0001213900-26-098219 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9000 (−6.25%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9000 (−9.64%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9000 (−9.09%) |
Oct 14, 2026 13d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9000 (−16.67%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9000 (−29.13%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9000 (−39.19%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9000 (−44.44%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9000 (+42.74%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9000 (−45.45%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9000 (−55.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers